Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
pfizer
4
×
san diego blog main
4
×
san diego top stories
amgen
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
medicare
merck
national
novartis
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
cancer
clinical trials
deals
diagnostics
gene therapy
immunotherapy
president trump
What
patients
4
×
bio
drug
roundup
pfizer
sets
acquisitions
advantages
ago
akcea
albert
alnylam
amyloidosis
approved
attr
available
bar
battle
becker
biggest
billions
bourla
brings
ceo
company
crispr
debilitating
disease
dollars
eaton
expect
fda
future
gamble
gene
genetic
healthcare
impact
imports
life
Language
unknown
unset
Current search:
pfizer
×
patients
×
" san diego blog main "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
